Enterofuril (nifuroxazide) suspension 200 mg/5 ml. 90 ml. №1

$22.40

Manufacturer: Bosnia and Herzegovina

Acute diarrhea of infectious etiology.

Category:

Description

ENTEROFURIL COMPOSITION
active substance: nifuroxazide

5 ml of suspension contains 200 mg of nifuroxazide

excipients: sucrose, carbomer, banana flavor, sodium hydroxide, methyl parahydroxybenzoate (E 218), ethanol 96%, citric acid, purified water.

DOSAGE FORM
Oral suspension.

MAIN PHYSICAL AND CHEMICAL PROPERTIES:
thick yellow suspension with a banana odor.

PHARMACOLOGICAL GROUP
Antimicrobial agents used to treat intestinal infections.

ATX code A07A X03.

PHARMACOLOGICAL PROPERTIES
Pharmacological.

Nifuroxazide is an antimicrobial drug derived from nitrofuran. The mechanism of action is not fully understood. The antimicrobial and antiparasitic properties of nifuroxazide are possibly due to the presence of an amino group. Local activity and the lack of penetration into the organs and tissues of the body makes nifuroxazide unique in comparison with other nitrofuran derivatives, since there is no systemic effect of this antidiarrheal drug. Effective against gram-positive and gram-negative bacteria: Streptococcus pyogenes, Staphylococcus aureus, E. coly, Salmonellae, Shigellae.

Pharmacokinetics.

After oral administration, nifuroxazide is practically not absorbed from the gastrointestinal tract and does not enter the organs and tissues, 99% of the applied drug remains in the intestine. Nifuroxazide metabolism occurs in the intestine, about 20% of the amount taken is excreted unchanged. Nifuroxazide and its metabolites are excreted in the feces. The rate of elimination of the drug depends on the amount of the drug taken and on the motility of the gastrointestinal tract. In general, the withdrawal of nifuroxazide is slow; it remains in the gastrointestinal tract for a long time.

In therapeutic doses, nifuroxazide practically does not suppress the normal intestinal microflora, does not cause the appearance of resistant microbial forms, as well as the development of cross-resistance of bacteria to other antibacterial drugs. The therapeutic effect is achieved from the first hours of treatment.

INDICATIONS
Acute diarrhea of ​​infectious etiology.

CONTRAINDICATIONS
Hypersensitivity to nifuroxazide, other 5-nitrofuran derivatives or other components of the drug.

INTERACTION WITH OTHER DRUGS AND OTHER INTERACTIONS
Nifuroxazide is not recommended to be used simultaneously with sorbents, drugs that contain alcohol, drugs that can cause antabuse reactions, and drugs that depress the central nervous system.

FEATURES OF APPLICATION
Treatment with Nifuroxazide does not exclude dietary regimen and rehydration. If necessary, apply concomitant rehydration therapy, depending on the age and condition of the patient and the intensity of diarrhea.

Prevention or treatment of dehydration should be done orally or with solutions. If rehydration is intended, it is recommended to use solutions intended for this purpose, in accordance with the instructions for dilution and use. The volume of oral rehydration solutions provided is dependent on weight loss. In case of severe diarrhea, intense vomiting and refusal to eat, intravenous rehydration is required.

If there is no need for such rehydration, it is necessary to compensate for the loss of fluid by drinking a large number of drinks containing salt and sugar (based on the average daily requirement of 2 liters of water).

Consideration should be given to dietary recommendations during diarrhea: avoid eating fresh vegetables and fruits, spicy foods, frozen foods and drinks. Rice should be preferred. The decision to use dairy products is made on a case-by-case basis.

APPLICATION DURING PREGNANCY OR BREASTFEEDING
There is insufficient data on possible teratogenic and fetotoxic effects when using nifuroxazide during pregnancy. Therefore, as a precautionary measure, the use of nifuroxazide during pregnancy is not recommended.

The drug can be used in women during lactation with short-term treatment with Nifuroxazide.

ABILITY TO INFLUENCE THE RATE OF REACTION WHEN DRIVING A VEHICLE OR OTHER MECHANISMS
Does not affect.

DOSAGE AND APPLICATION
Take orally, with or without food. The suspension should be shaken before use. The maximum daily dose of nifuroxazide is 800 mg.

Children aged 2 years and older: 5 ml of suspension 3 times a day.

Adults: 5 ml of suspension 4 times a day.

The duration of treatment is no more than 7 days.

CHILDREN
Do not administer to children under 2 years of age.

OVERDOSE
Overdose cases are not described. In case of exceeding the dose, recogastric lavage and symptomatic treatment are recommended.